Wockhardt Ltd

WOCKPHARMA

Watchlist

AI Mode

‌

Market Cap

₹ 21,770 Cr

P/E

308.70

‌

‌
‌

‌

‌
‌

Investment Checklist

How to read checklist?

Performance

MARKET LEADER

Valuation

OVERVALUED

Growth

STABLE

Profitability

LOW MARGIN

Technicals

Bearish

Risk

HIGH RISK

Investment Checklist

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

Price

PE Ratio

Price

‌

Overview

Detailed Summary

Wockhardt Limited is a global pharmaceutical and biotechnology company with a strong focus on research-driven pharmaceuticals, particularly in antibiotics and biotech drug development.

The company achieved a notable 67% growth in EBITDA in the past year, driven by operational excellence and significant debt reduction initiatives, improving its financial health markedly.

Wockhardt's rich pipeline includes multiple new chemical entities (NCEs), unique antibiotics that address superbug challenges, illustrating its leadership in novel antibiotic discovery, especially with successful Phase 3 trials for drugs like ZAYNICH.

Wockhardt plans to double its business in the next three years by expanding capacity and tapping into the growing demand for its diabetes and novel antibiotic portfolios, highlighting strategic growth plans.

It has garnered significant global recognition with Qualified Infectious Disease Programme status for five antibacterial drugs from the USFDA, underlining its global standing in addressing serious infectious diseases.

Sector

Pharmaceuticals

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln M/S

Market Cap

21,770 Cr

Volatility

High Risk

P/E Ratio

308.7

Industry P/E

30.8

PEG Ratio

3.5

P/B Ratio

4.8

52W High

1,870.00

52W Low

1,109.60

Sales CAGR

7.65%

-2.30%

1.15%

10Y

-4.25%

Profit CAGR

87.92%

—

10Y

—

ROE

TTM

1.54%

-8.92%

-3.14%

10Y

-3.89%

ROCE

TTM

4.05%

-1.31%

-2.53%

10Y

-1.35%

Technicals

‌

Forecasts

Peers

Symbol	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
JBCHEPHARM	1793.95	28,074 Cr	39.08	7.38	0.86	18.88	25.16	15.24
EMCURE	1396.00	26,475 Cr	33.00	5.58	0.21	16.72	19.37	8.72
WOCKPHARMA	1341.00	21,770 Cr	308.70	4.77	0.00	1.54	4.05	-0.60
COHANCE	531.75	20,289 Cr	59.06	5.36	0.00	8.61	9.19	5.63
NATCOPHARM	905.10	16,211 Cr	10.54	1.87	0.66	17.79	21.15	14.73
CONCORDBIO	1362.65	14,256 Cr	44.00	7.80	0.64	17.73	23.48	15.99
GRANULES	571.00	13,864 Cr	27.14	3.48	0.26	12.88	13.37	7.39

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

AI Mode

Consolidated Quarterly Results (in ₹ Crores)

View Standalone

Total Figures

QoQ Changes

Total Figures

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Sales	644	753	701	700	739	809	721	743	738	782
Expenses	628	681	664	803	648	699	593	679	666	604
Operating Profit	16	72	37	-103	91	110	128	64	72	178
OPM %	2.48	9.56	5.28	-14.71	12.31	13.60	17.75	8.61	9.76	22.76
Other Income	0.00	24	8.00	54	30	9.00	8.00	15	-77	21
Interest	79	76	77	73	73	73	60	48	48	55
Depreciation	55	55	55	58	54	55	55	53	56	53
Profit Before Tax	-118	-35	-87	-180	-6.00	-9.00	21	-22	-109	91
Tax %	-15.25	-108.57	1.15	1.67	-166.67	-77.78	4.76	-104.55	0.92	9.89
Net Profit	-136	-73	-86	-177	-16	-16	20	-45	-108	82
EPS in Rs	-8.23	-4.76	-5.10	-10.99	-0.90	-1.39	0.91	-1.57	-5.53	4.81

Consolidated Profit Loss (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	4,015	3,937	3,566	2,844	2,708	3,230	2,651	2,798	3,012	3,011
Expenses	4,002	3,935	3,604	2,725	2,771	2,932	2,550	2,759	2,619	2,637
Operating Profit	13	1.83	-38	119	-63	298	101	39	393	374
OPM %	0.32	0.05	-1.08	4.19	-2.33	9.23	3.81	1.39	13.05	12.42
Other Income	114	-238	21	39	-10	-163	-172	69	62	-45
Interest	225	255	265	276	249	299	302	305	254	229
Depreciation	149	150	164	224	246	247	251	223	217	219
Profit Before Tax	-247	-641	-447	-342	-568	-411	-624	-420	-16	-119
Tax %	8.54	-4.01	30.18	59.67	47.71	32.12	0.48	-12.38	-256.25	-25.21
Net Profit	-226	-667	-312	-138	-297	-279	-621	-472	-57	-149
EPS in Rs	-13.10	-38.23	-12.86	-4.30	41.98	-18.09	-34.38	-29.08	-2.94	-1.38
Dividend Payout %	-56.47	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—

Consolidated Balance Sheet (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	55	55	55	55	55	55	72	72	77	81
Reserves	3,720	3,281	2,797	2,619	2,616	3,321	3,777	3,282	3,282	4,272
Borrowings	2,471	3,853	2,610	2,453	2,514	2,674	2,198	2,184	2,356	2,021
Other Liabilities	1,875	1,832	2,700	2,716	2,993	1,724	2,196	2,145	1,934	1,761
Total Liabilities	8,121	9,022	8,162	7,844	8,179	7,774	8,243	7,683	7,649	8,135
Fixed Assets	2,809	2,773	2,888	3,058	3,502	3,343	3,462	3,042	2,881	2,736
CWIP	1,036	1,244	1,433	1,445	1,585	1,379	1,342	1,539	1,722	2,033
Investments	0.45	563	214	0.45	0.45	0.00	0.00	0.00	0.00	422
Other Assets	4,276	4,442	3,628	3,340	3,092	3,052	3,439	3,102	3,046	2,944
Total Assets	8,121	9,022	8,162	7,844	8,179	7,774	8,243	7,683	7,649	8,135

Consolidated Cash Flows (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	-42	-269	68	183	649	-287	413	153	219	-22
Cash from Investing Activity	-106	-687	630	95	-156	1,470	-201	-125	-137	-783
Cash from Financing Activity	193	1,254	-769	-776	-680	-1,171	-71	-315	334	409
Net Cash Flow	46	298	-71	-499	-186	12	141	-287	416	-396

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Nov 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Promoters	59.31%	58.40%	55.14%	54.93%	51.60%	51.99%	51.99%	49.09%	49.09%	49.09%	49.09%	49.08%
FIIs	2.77%	2.59%	3.01%	4.16%	5.49%	5.92%	6.69%	6.61%	6.54%	6.81%	7.28%	7.09%
DIIs	0.23%	0.20%	0.23%	0.35%	4.85%	4.47%	5.11%	9.90%	9.84%	10.61%	11.03%	11.03%
Public	37.69%	38.81%	41.61%	40.56%	38.06%	37.61%	36.21%	34.39%	34.53%	33.50%	32.60%	32.79%
Total Shareholders	1,82,493	1,78,915	1,72,989	1,61,813	1,46,138	1,40,391	1,38,142	1,43,876	1,42,710	1,41,799	1,46,918	1,37,946

Market Transactions

Date	Party	Category	Type	Avg Price (₹)	Total Value (₹)	Quantity	Percent Traded
Dec 27, 2024	Muayyad khorakiwala	Insider - Immediate Relative	Acquisition	—	—	1,800	—
Nov 16, 2023	Qe securities llp	Bulk	Sell	313.75	33.48 Cr	10,66,935	0.65
Nov 16, 2023	Qe securities llp	Bulk	Buy	313.65	31.90 Cr	10,17,212	0.62
Jun 19, 2023	Graviton research capital llp	Bulk	Sell	225.91	19.49 Cr	8,62,923	0.53
Jun 19, 2023	Graviton research capital llp	Bulk	Buy	225.86	19.42 Cr	8,59,924	0.52
Jun 16, 2023	Graviton research capital llp	Bulk	Sell	213.06	27.76 Cr	13,02,931	0.80
Jun 16, 2023	Qe securities	Bulk	Sell	212.77	16.99 Cr	7,98,734	0.49
Jun 16, 2023	Graviton research capital llp	Bulk	Buy	213.04	27.82 Cr	13,05,930	0.80
Jun 16, 2023	Qe securities	Bulk	Buy	213.36	17.05 Cr	7,99,022	0.49

Projection

Actions

Action Type

‌
‌

Announcements

Last 7 days

Newest

Sentiment

Shareholder Meeting

17 hours ago

Voting Results and Scrutinizer's Report

The Postal Ballot results indicate that the Special Resolution for the appointment of Mr. Om Prakash Bhatt as Non-Executive Independent Director has been duly passed.

Postal Ballot Result

17 hours ago

Outcome of Postal Ballot on Director Appointment

Wockhardt Limited has confirmed the successful passing of a Special Resolution to appoint Mr. Om Prakash Bhatt as a Non-Executive Independent Director for a term of five years, effective from November 3, 2025.

Documents

Presentations

Concalls

Reports

Presentations

Investor Presentation

Q4 FY25

Investor Presentation

Q3 FY25

Investor Presentation

Q2 FY25

Investor Presentation

Q3 FY24

Investor Presentation

Q3 FY23

Investor Presentation

Q3 FY22

AI Mode

Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.

AI Mode

Peers

Symbol	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
JBCHEPHARM	1793.95	28,074 Cr	39.08	7.38	0.86	18.88	25.16	15.24
EMCURE	1396.00	26,475 Cr	33.00	5.58	0.21	16.72	19.37	8.72
WOCKPHARMA	1341.00	21,770 Cr	308.70	4.77	0.00	1.54	4.05	-0.60
COHANCE	531.75	20,289 Cr	59.06	5.36	0.00	8.61	9.19	5.63
NATCOPHARM	905.10	16,211 Cr	10.54	1.87	0.66	17.79	21.15	14.73
CONCORDBIO	1362.65	14,256 Cr	44.00	7.80	0.64	17.73	23.48	15.99
GRANULES	571.00	13,864 Cr	27.14	3.48	0.26	12.88	13.37	7.39

Overview

Detailed Summary

Wockhardt Limited is a global pharmaceutical and biotechnology company with a strong focus on research-driven pharmaceuticals, particularly in antibiotics and biotech drug development.

The company achieved a notable 67% growth in EBITDA in the past year, driven by operational excellence and significant debt reduction initiatives, improving its financial health markedly.

Sector

Pharmaceuticals

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln M/S

Market Cap

21,770 Cr

Volatility

High Risk

P/E Ratio

308.7

Industry P/E

30.8

PEG Ratio

3.5

P/B Ratio

4.8

52W High

1,870.00

52W Low

1,109.60

Sales CAGR

7.65%

-2.30%

1.15%

10Y

-4.25%

Profit CAGR

87.92%

—

10Y

—

ROE

TTM

1.54%

-8.92%

-3.14%

10Y

-3.89%

ROCE

TTM

4.05%

-1.31%

-2.53%

10Y

-1.35%

Wockhardt Ltd

Wockhardt Ltd

WOCKPHARMA

AI Mode

Investment Checklist

Investment Checklist

Overview

Sector

Industry

Market Cap

Volatility

P/E Ratio

Industry P/E

PEG Ratio

P/B Ratio

52W High

52W Low

Technicals

Forecasts

Peers

Price Chart Comparison

Financial Statements

AI Powered Summary

AI Mode

Consolidated Quarterly Results (in ₹ Crores)

Consolidated Profit Loss (in ₹ Crores)

Consolidated Balance Sheet (in ₹ Crores)

Consolidated Cash Flows (in ₹ Crores)

Shareholdings

Shareholding History

Market Transactions

Projection

Actions

Announcements

Documents

AI Mode

AI Mode

Technicals

Forecasts

Oscillators

Neutral

Overall

Bearish

Moving Averages

Bearish

Overall

Bearish

Wockhardt Ltd

WOCKPHARMA

AI Mode

Projection

Peers

Price Chart Comparison

Announcements

Overview

Sector

Industry

Market Cap

Volatility

P/E Ratio

Industry P/E

PEG Ratio

P/B Ratio

52W High

52W Low

Investment Checklist